Difference between revisions of "Prostate cancer with neuroendocrine differentiation"

From Libre Pathology
Jump to navigation Jump to search
(split out)
 
(tweak)
Line 1: Line 1:
'''Neuroendocrine carcinoma of the prostate''' is a rare group of [[prostate cancer]]s that is hypothesized to evolve in the context androgen deprivation therapy.<ref name=pmid24705311>{{Cite journal  | last1 = Epstein | first1 = JI. | last2 = Amin | first2 = MB. | last3 = Beltran | first3 = H. | last4 = Lotan | first4 = TL. | last5 = Mosquera | first5 = JM. | last6 = Reuter | first6 = VE. | last7 = Robinson | first7 = BD. | last8 = Troncoso | first8 = P. | last9 = Rubin | first9 = MA. | title = Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. | journal = Am J Surg Pathol | volume = 38 | issue = 6 | pages = 756-67 | month = Jun | year = 2014 | doi = 10.1097/PAS.0000000000000208 | PMID = 24705311 }}</ref>
'''Prostate cancer with neuroendocrine differentiation''' is a rare group of [[prostate cancer]]s that is hypothesized to evolve in the context androgen deprivation therapy.<ref name=pmid24705311>{{Cite journal  | last1 = Epstein | first1 = JI. | last2 = Amin | first2 = MB. | last3 = Beltran | first3 = H. | last4 = Lotan | first4 = TL. | last5 = Mosquera | first5 = JM. | last6 = Reuter | first6 = VE. | last7 = Robinson | first7 = BD. | last8 = Troncoso | first8 = P. | last9 = Rubin | first9 = MA. | title = Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. | journal = Am J Surg Pathol | volume = 38 | issue = 6 | pages = 756-67 | month = Jun | year = 2014 | doi = 10.1097/PAS.0000000000000208 | PMID = 24705311 }}</ref>


'''Neuroendocrine carcinoma of the prostate''' redirect here.
==Subclassification==
It is subclassified as per Epstein ''et al.'':<ref name=pmid24705311/>
It is subclassified as per Epstein ''et al.'':<ref name=pmid24705311/>
*Usual prostate adenocarcinoma with neuroendocrine differentiation.
*Usual prostate adenocarcinoma with neuroendocrine differentiation.

Revision as of 16:31, 19 March 2018

Prostate cancer with neuroendocrine differentiation is a rare group of prostate cancers that is hypothesized to evolve in the context androgen deprivation therapy.[1]

Neuroendocrine carcinoma of the prostate redirect here.

Subclassification

It is subclassified as per Epstein et al.:[1]

  • Usual prostate adenocarcinoma with neuroendocrine differentiation.
  • Adenocarcinoma with Paneth cell neuroendocrine differentiation.
  • Carcinoid tumour of the prostate.
  • Small cell carcinoma of the prostate gland.
  • Large cell neuroendocrine carcinoma of the prostate.
  • Mixed (small and/or large cell) neuroendocrine carcinoma-acinar adenocarcinoma.

IHC

  • PSA typically negative in NE carcinoma.

See also

References

  1. ↑ 1.0 1.1 Epstein, JI.; Amin, MB.; Beltran, H.; Lotan, TL.; Mosquera, JM.; Reuter, VE.; Robinson, BD.; Troncoso, P. et al. (Jun 2014). "Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.". Am J Surg Pathol 38 (6): 756-67. doi:10.1097/PAS.0000000000000208. PMID 24705311.
Retrieved from "https://librepathology.org/w/index.php?title=Prostate_cancer_with_neuroendocrine_differentiation&oldid=48792"